Combined in silico docking and in vitro antiviral testing for drug repurposing identified lurasidone and elbasvir as SARS-CoV-2 and HCoV-OC43 inhibitors
M. Milani, M. Donalisio, R. M. Bonotto, E. Schneider, I. Arduino, F. Boni, D. Lembo, A. Marcello, E. Mastrangelo
The paper identifies lurasidone and elbasidone as inhibitors of SARS-CoV-2 and HCoV-OC43 through in silico docking and in vitro testing.
bioRxiv · Nov 12, 2020Pharmacology & Toxicology